secwatch.observer — SEC 8-K summary
======================================

Issuer:     Context Therapeutics Inc. (CNTX)
CIK:        0001842952
Form:       8-K
Filed at:   2023-06-02T23:59:59+00:00
Accession:  0001842952-23-000065
Event type: other_material
Sentiment:  negative
Materiality: 0.50
Item codes: 5.07
LLM model:  deepseek-v4-flash:cloud@v2

Context Therapeutics 2023 annual meeting: auditor ratified, reverse stock split not approved
--------------------------------------------------------------------------------

- Ratification of CohnReznick LLP as independent auditor for FY2023 approved with 9,827,096 for, 232,432 against, 109,961 abstentions.
- Proposal to amend charter for reverse stock split (1:2 to 1:50) failed: 7,809,550 for, 2,326,090 against, 33,849 abstentions, not reaching majority of outstanding shares.
- Quorum of 63.69% (10,169,489 shares) present at May 31, 2023 annual meeting.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1842952/000184295223000065/0001842952-23-000065-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1842952/000184295223000065/cntx-20230531.htm
  HTML page:      https://secwatch.observer/filing/0001842952-23-000065

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer